NCT03462043View on ClinicalTrials.gov

A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 10, 2018

Primary Completion Date

November 20, 2018

Study Completion Date

December 30, 2018

Conditions
Parkinson
Interventions
COMBINATION_PRODUCT

ND0612

s.c. infused

COMBINATION_PRODUCT

CLES

Carbidopa-Levodopa Enteral Suspension.

Trial Locations (1)

00163

91601, Roma

Sponsors

Lead Sponsor

NeuroDerm Ltd.
All Listed Sponsors
lead

NeuroDerm Ltd.

INDUSTRY

NCT03462043 - A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension | Biotech Hunter | Biotech Hunter